Podcasts about atherosclerotic

Commentary by Dr. Candice Silversides

Commentary by Dr. Candice Silversides

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Dr. Vyvyane Loh returns to STEM-Talk for her second appearance to talk about atherosclerotic heart disease. Also known as ASCVD, the disease has been reported to affect 26 million people in the U.S., and annually leads two million hospitalizations and more than 400,000 deaths. Vyvyane is a board-certified physician in obesity and internal medicine. In episode 142 of STEM-Talk, we talked to Vyvyane about her Boston-based preventative-care practice that specializes in weight management and the treatment of chronic metabolic diseases such as diabetes, hypertension and dyslipidemia. In today's podcast, Vyvyane and host Dr. Ken Ford talk about ASCVD as well as recent research that has shown substantial individual variability in the response to statin therapy as a way to lower cardiovascular risk. Vyvyane and Ken also discuss how the current knowledge base informing clinical practice in medicine today is far behind advances in the biological sciences, especially in the field of ASCVD. Show notes:  [00:03:15] Ken welcomes Vyvyane back to STEM-Talk and encourages listeners to check out Vyvyane's first interview, episode 142. Ken goes on to mention that atherosclerotic heart disease has been reported to affect 26 million people in the U.S. and that despite the wide use of statins as a primary prevention of atherosclerotic heart disease, the effects of this treatment have been variable with regards to major adverse cardiac events. Ken asks Vyvyane for her thoughts. [00:05:32] Ken asks Vyvyane about recent developments in atherosclerotic heart disease research, specifically in regard to the anatomical aspects of the disease-model itself. [00:08:43] Ken follows up asking Vyvyane how the knowledge we have of glycocalyces, and the endothelial lining of the blood vessels, could affect clinical practice. [00:12:19] Ken asks if there are any other recent updates to the anatomical model of atherosclerotic disease that people should be aware of. [00:13:09] Ken asks Vyvyane how she would characterize the significance of the tunica intima of the coronary artery. [00:15:25] Ken asks about the third recent anatomical highlight to blood vessels relevant to the discussion. [00:19:19] Ken follows up, asking if this is how the vasa vasorum contributes to our understanding of the development of atherosclerosis. [00:21:05] Ken asks Vyvyane to explain what endothelial dysfunction is and what are its downstream effects. [00:26:09] Ken asks Vyvyane to expound on the link between atherosclerotic disease and auto-immunity. [00:31:01] Ken asks, given the link to inflammation, if there have been any therapeutic developments made in the treatment of atherosclerotic disease. [00:34:54] Ken asks about the vaccine that is being developed for atherosclerosis. [00:37:53] Ken mentions that another recent development in the field is the growing appreciation for clonal hematopoiesis in atherosclerosis. Ken asks Vyvyane to explain what clonal hematopoiesis is. [00:39:55] Ken asks Vyvyane what some actionable takeaways are from our discussion on atherosclerosis that listeners can take home with them. [00:43:17] Ken asks Vyvyane about her passion for dance, and how much time she invests in that area of her life. [00:48:11] Ken follows up asking Vyvyane what drives her to pursue dance so passionately. [00:53:34] In closing the interview, Ken encourages listeners to check out Vyvyane's podcast as well as her website. Links: Vyvyane Loh website Vlmdrounds.com Learn more about IHMC STEM-Talk homepage Ken Ford bio Ken Ford Wikipedia page  

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Sigrid Nilsson, AT-läkare, doktorand, presenterar deras forskning inom arterosklerotisk sjukdom och dess relation till vasomotoriska symtom. Symtom som de flesta kvinnor upplever någon gång under menopausen. PP-ELI-SWE-2801  

Are you up to date on the latest lipid-lowering therapies? Drs Zambon and Taub discuss. Credit available for this activity expires: 9/13/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996295?ecd=bdc_podcast_libsyn_mscpedu

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.12.548696v1?rss=1 Authors: Karnewar, S., Karnewar, V., Shankman, L. S., Owens, G. K. Abstract: The use of senolytic agents to remove senescent cells from atherosclerotic lesions is controversial. A common limitation of previous studies is the failure to rigorously define the effects of senolytic agent ABT-263 (Navitoclax) on smooth muscle cells (SMC) despite studies claiming that they are the major source of senescent cells. Moreover, there are no studies of the effect of ABT-263 on endothelial cells (EC), which along with SMC comprise 90% of -SMA+ myofibroblast-like cells in the protective fibrous cap. Here we tested the hypothesis that treatment of advanced atherosclerotic mice with the ABT-263 will reduce lesion size and increase plaque stability. SMC (Myh11-CreERT2-eYFP) and EC (Cdh5-CreERT2-eYFP) lineage tracing Apoe-/- mice were fed a WD for 18 weeks, followed by ABT-263 100mg/kg/bw for six weeks or 50mg/kg/bw for nine weeks. ABT-263 treatment did not change lesion size or lumen area of the brachiocephalic artery (BCA). However, ABT-263 treatment reduced SMC by 90% and increased EC-contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60%. ABT-263 treatment also reduced -SMA+ fibrous cap thickness by 60% and increased mortality by greater than 50%. Contrary to expectations, treatment of WD-fed Apoe-/- mice with the senolytic agent ABT-263 resulted in multiple detrimental changes including reduced indices of stability, and increased mortality. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Commentary by Dr. Candice Silversides

Commentary by Dr. Valentin Fuster

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.02.526873v1?rss=1 Authors: Maringanti, R., van Dijk, C. G. M., Meijer, E. M., Brandt, M. M., Krebber, M. M., Chrifi, I., Duncker, D. J., Verhaar, M. C., Cheng, C. Abstract: Background: Atherosclerosis is a complex inflammatory vascular disease characterized by lipid and immune cells accumulation in the vessel wall, leading to lumen narrowing. Although several 3D in vitro microfluidic systems were previously described, a realistic reconstruction of the in vivo human atherosclerotic environment requires co-culture of different cell types arranged in atherosclerotic vessel-like structures with exposure to flow and circulating cells, creating challenges for disease modelling. In this study we developed a 3D tubular microfluidic model with quadruple coculture of human aortic smooth muscle cells (hAoSMCs), human umbilical cord vein endothelial cells (HUVECs) and foam cells to re-create a complex human atherosclerotic vessel in vitro to study the effect of flow and circulating immune cells. Methods & Results: Our new co-culture protocol with BFP-labelled hAoSMCs, GFP-labelled HUVECs and THP-1 macrophages-derived, Dil-labelled Oxidized Low-Density Lipoprotein (Dil-Ox-LDL) foam cells in a fibrinogen-collagen-I based 3D extracellular matrix (ECM) resulted in vessels with an early lesion morphology, showing a layered vessel-like composition with an endothelium and media, with foam cells accumulating in the sub-endothelial space. Perfusion for 24 hours of atherosclerotic and "healthy" vessels (BFP hAoSMCs and GFP HUVECs without foam cells) showed that the layered wall composition remained stable. Perfusion with circulating THP-1 monocytes demonstrated cell extravasation into the atherosclerotic vessel wall and recruitment of THP-1 cells to the foam cell core. QPCR analysis revealed increased expression of atherosclerosis markers in the atherosclerotic vessels and adaptation in VSMCs migration to flow and the plaque microenvironment, compared to control vessels. Conclusion: We present a 3D tubular microfluidic model of a complex early atherosclerotic human vessel that can be exposed to flow and circulating THP-1 monocytes to study hemodynamic changes and immune cell recruitment under live confocal imaging. This novel atherosclerosis-on-a-chip model offers a humanized platform for in-depth mechanistic in vitro studies and drug testing. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Commentary by Dr. Valentin Fuster

Commentary by Dr. Jesus Jimenez

Dr. Scott Cameron discusses the diagnoses of non-atherosclerotic lower extremity arterial disease.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Commentary by Dr. Valentin Fuster

Atherosclerotic cardiovascular disease (ASCVD) involves the buildup of cholesterol plaque in arteries and includes acute coronary syndrome, peripheral arterial disease, and events such as myocardial infarction and stroke Pat was joined on the show by Dr. Paddy Barrett, Preventative Cardiologist at Blackrock Clinic about the latest campaign for ASCVD Awareness

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

Commentary by Seokhun Yang

With Paul Ridker, Brigham and Women's Hospital, Boston - USA & Nader Rifai,  Boston Children's Hospital - USA. Link to paper Link to editorial

CME credits: 0.75 Valid until: 25-02-2023 Claim your CME credit at https://reachmd.com/programs/mastering-management-ascvd-risk/omega-3-icosapent-ethyl-and-stroke-reduction-in-atherosclerotic-vascular-disease/13545/ Hear about the hottest ASCVD topics presented at the International Stroke Conference! Topics range from the latest data to risk factors to watch out for across the spectrum of disease. A stroke neurologist and 2 international experts in managing ASCVD provide hard-hitting and timely information that you can put into practice today.

CME credits: 0.75 Valid until: 25-02-2023 Claim your CME credit at https://reachmd.com/programs/mastering-management-ascvd-risk/omega-3-icosapent-ethyl-and-stroke-reduction-in-atherosclerotic-vascular-disease/13545/ Hear about the hottest ASCVD topics presented at the International Stroke Conference! Topics range from the latest data to risk factors to watch out for across the spectrum of disease. A stroke neurologist and 2 international experts in managing ASCVD provide hard-hitting and timely information that you can put into practice today.

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

A case-based Review on HTN and DLP management

Whilst Aortic Pathologies may not be the most common emergency condition paramedics are presented with, they are most definitely among the most devastating. Atherosclerotic degenerative aneurysms and aortic dissection are often misunderstood and misdiagnosed and they can present a number of challenges to clinicians in the pre-hospital arena. So, this month, we're looking at some Aortic disease pathologies and everything you aorta know about them.

Commentary by Dr. Valentin Fuster

CardioNerds Tommy Das (Program Director of the CardioNerds Academy and cardiology fellow at Cleveland Clinic) and Rick Ferraro (Director of CardioNerds Journal Club and cardiology fellow at the Johns Hopkins Hospital) join Dr. Erin Michos (Associate Professor of Cardiology at the Johns Hopkins Hospital and Editor-In-Chief of the American Journal of Preventative Cardiology) for a discussion about the effect of DHA and EPA on triglycerides and why DHA/EPA combinations may have exhibited limited benefits in trials. This episode is part of the CardioNerds Lipids Series which is a comprehensive series lead by co-chairs Dr. Rick Ferraro and Dr. Tommy Das and is developed in collaboration with the American Society For Preventive Cardiology (ASPC). Relevant disclosures: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Lipid Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls The best intervention for heart disease is prevention! The InterHeart trial showed that 9 modifiable risk factors (dyslipidemia, smoking, hypertension, diabetes, abdominal obesity, dietary patterns, physical activity, consumption of alcohol, and psychosocial factors) predict 90% of acute myocardial infarction. So many acute events can be prevented1.Atherosclerotic vascular disease events increase across a range of triglyceride levels, even from 50-200mg/dL. So even in a relatively normal range, lower triglycerides seem to be better. Over ¼ of US adults have triglycerides over 150.While 8% of US adults take fish oil supplements, multiple meta-analyses have failed to show any benefit to the use of dietary omega-3 supplementation2. Dietary supplements these are not meant for medical use and are not studied or regulated as such! Show notes 1. What are DHA and EPA? DHA, or docosahexaenoic acid, and EPA, or eicosapentaenoic acid, are n-3 polyunsaturated fatty acids, also known as omega-3 fatty acids. These compounds have been of considerable interest for over two decades given observed association of high dietary omega-3 fatty acid intake with reduced cardiovascular events3. As both are important omega-3 fatty acids, trials on the benefits of DHA and EPA have often focused on the two compounds in combination. 2. What was the GISSI-Prevenzione Trial and why was it Important? GISSI-Prevenzione trial (Lancet 1999), was one of the earliest trials to study DHA and EPA4. In this trial, the authors evaluated the effect of omega-3 supplementation as a combination pill of DHA and EPA on cardiovascular events and death in patients with recent myocardial infarction (the last three months). Over a 3.5-year follow-up period, participants treated with DHA/EPA combination experienced a significant reduction in death, nonfatal MI, and stroke.As this was an early trial, patients were largely not on statins, as these were not supported at the time of study initiation (Only 5% were on cholesterol-lowering medications at baseline, and only 45% were on cholesterol-lowering therapy at study completion). The benefits seen in this trial may not extend to modern practice with patients on contemporary background therapy.The trial participants were also not representative of our modern patients for a variety of other reasons. 85% of participants in the trial were men. 42.2% of patients in EPA/DHA arm were current smokers, and 35.4% were prior smokers. Only 14.2% of patients had diabetes and 14.7% with BMI >30.Notably, the decrease in triglycerides in this trial was only 3%, implying that triglyceride lowering did not entirely explain the benefit in cardiovascular events seen. 3. What about the data after the GISSI-Prevensione Trial? After this positive trial for DHA/EPA in combination, subsequent trial data in support of DHA/EPA has been less robust.

Innovation World Podcast Series welcomes young innovator Duaa Raza, 12th grader from  Wayne, New Jersey, discussing her medical invention called "CRISPRi-dCas9 Novel Gene Therapy for the Treatment of Atherosclerotic  Predisposition to Coronary Artery Diseases.   Listen to more young innovators: https://www.buzzsprout.com/1589629/episodesJoin Innovation World in Inspiring Creativity, Innovation and Entrepreneurship in K-12 and Beyond. https://innovationworld.org/

Commentary by Dr. Douglas Mann

That there are senescence-associated decreases in the JAK-STAT signaling transduction cascade has been observed in human lymphocyte lineages. This phenomena, as associated with a decreased JAK- tyrosine phosphorylation of STAT5, is linked to plasma membrane cholesterol content. Therefore, plasma membrane cholesterol content is involved in T cells modulation and proliferation. Acid sphingomyelinase- mediated ceramide lipid raft mobilization and aggregation of membrane receptors plays a crucial role in this pathobiochemical dynamic leading to multiple disease and comorbidity states in the elderly. Classical Papers Examined: Mech Ageing Dev. 2001 Sep 15;122(13):1413-30 Cytometry A. 2006 Mar;69(3):189-91 J Lipid Res. 2007 Jan;48(1):19-29. doi: 10.1194 --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message Support this podcast: https://anchor.fm/dr-daniel-j-guerra/support

Commentary by Dr. Chern-En Chiang

Commentary by Dr. Valentin Fuster

The Patient with Early Atherosclerotic Disease-What to Do, What Not to Do Guest: Francisco Lopez-Jimenez, M.D., M.B.A. (@CVDprevention) Host: Stephen L. Kopecky, M.D. (@DrSteveKopecky) Many people have a family history of atherosclerotic disease — heart attacks, strokes or blockages in the body's arteries caused by cholesterol plaques. If atherosclerosis occurs at an early age or affects multiple family members, or if the family history includes sudden death, there is cause for concern. Joining us today to discuss family history of early atherosclerotic disease and its impact on cardiovascular health is Francisco Lopez-Jimenez, M.D., M.B.A., chair of Preventive Cardiology at Mayo Clinic in Rochester, Minnesota. Specific topics discussed: Concerns generated by a family history of atherosclerosis Genetic markers for atherosclerotic disease Impact of genes vs. lifestyle on the likelihood of atherosclerosis When and how to conduct genetic testing Treatment for peripheral arterial disease and cerebrovascular disease What not to do for patients with atherosclerosis Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. No CME credit offered for this episode. Podcast transcript available here.

This episode, sponsored by an educational grant from Amarin Corporation, is a discussion around primary prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Professor Alberico Catapano, Professor of Pharmacology, The University of Milano, Italy, discusses practical considerations that address all aspects of a patient's lifestyle habits and estimated risk of a future ASCVD event, which is critical prior to deciding on the need for pharmacotherapy.